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A Urinary Diabetogenic Peptide in Proteinuric 
Diabetic Patients 
By LAWRENCE H. LOUIS AND JEROME W. CONN 
A polypeptide exhibiting diabetogenic 
and anti-insulin properties has been iso- 
lated from the urine of 33 of the 35 
proteinuric diabetic patients. This ma- 
terial could not be found in the urine of 
34 normal subjects and 32 diabetic pa- 
tients without proteinuria. It was, how- 
ever, detected chemically in one of seven 
nondiabetic patients with proteinuria, but 
the amount present was insufficient for 
biological testing. This polypeptide 
closely resembles, in physiochemical 
properties, that obtained from patients 
with lipoatrophic diabetes, as well as that 
isolated from the adenohypophyses of 
beef, sheep, and swine. The isoelectric 
point of the active polypeptide from all 
the above sources is approximately pH 
4.1. In one diabetic subject who under- 
went hypophysectomy, this material dis- 
appeared from the urine following the 
operation. It is suggested that the source 
of the active principle isolated from the 
urine of diabetic patients with proteinuria 
is probably the pituitary gland. (Metabo- 
lism 18: No. 7, July, 556563, 1969) 
I N 1963 WE REPORTED that the urine of patients with lipoatrophic dia- betes contains a diabetogenic po1ypeptide.l This has recently been con- 
fumed by others.2 We demonstrated that the peptide was capable of impairing 
glucose tolerance and of inducing insulin resistance when administered either 
to dogs or humans. The present study was designed to explore the possibility 
that a similar substance might be found in the urine of diabetic patients 
without lipodystrophy since a chance observation had disclosed its presence in 
an obese, maturity-onset diabetic. l Freshly collected urine samples from 67 
diabetic patients and 34 healthy subjects have been studied. The diabetogenic 
peptide was found in the urine of 33 of 35 diabetics with proteinuria but it 
was absent in all of 32 diabetics without proteinuria, as well as in the normal 
subjects. Seven additional subjects with proteinuria but without diabetes were 
studied. One of them exhibited a similar urinary material. 
MATERIALS AND METHODS 
Collection and preservation of urine samples were the same as previously described.1 
Clinical information on the proteinuric diabetic subjects studied are shown in Table 1. Our 
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more recent procedure for the isolation of the diabetogenic polypeptide (fraction I) from 
urine was employed.3 
Maintenance and preparation of dogs for glucose and insulin tolerance tests have been 
previously described.627 In the present studies, two well-trained dogs were employed. How- 
ever, because of the scarcity of the purified material, most of the tests were done on a 
small animal (Dog P, 7.4 Kg.). The assay procedure consisted of (a) a control glucose 
tolerance test done on day 1, and (b) an injection of the substance 10 hours before the 
second glucose tolerance test which was done on day 2. An interval of at least 13 days 
elapsed before the procedure was repeated in the same animal with the isolated peptide 
from another patient. 
Blood glucose was measured by the Somogyi-Nelson procedure.4 Disc electrophoresis was 
performed in a Model 6 apparatus* with a single bath assembly. The power source was 
Model 200.” Analyses were carried out according to the procedure of Ornstein and Davis.5 
Electrophoresis was carried out at room temperature at a current of 4 ma per tube for 30 
minutes. Polypeptide samples used were 60-100 pg. per tube. The buffer was of pH 8.3. 
Destaining was performed at a current of 12.5 ma per tube for 60 minutes. 
RESULTS 
An effort to determine the time of maximal biological effect was made by 
carrying out glucose tolerance tests 4 hours, 10 hours and 24 hours after an 
injection of the peptide (2 mg. per kilogram of dog body weight) from patient 
D.E.S. The results are presented in Fig. 1. In Dog P, it appears that the 
greatest effect occurred 10 hours after injection. Subsequendy, a11 tests were 
done 10 hours after administration of the peptide. Table 2 shows the effect 
*Canal Industrial Corp., RockviIle, Md. 
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73 142 140 116 111 74 67 
85 174 163 146 122 71 59 
93 154 143 111 75 93 88 
95 143 243 237 188 119 87 
88 124 148 138 81 74 88 
93 168 238 175 118 106 86 
77 138 166 156 80 59 72 
95 171 197 152 122 83 80 
84 119 161 122 74 72 73 
104 196 250 166 124 96 99 
84 139 128 118 67 71 89 
94 144 238 285 234 I99 131 
67 102 132 126 74 62 60 
89 123 133 91 62 78 81 
99 178 229 193 143 93 66 
78 125 151 117 66 74 81 
98 177 235 217 118 86 76 
83 130 156 122 104 60 63 
78 157 182 165 118 76 61 
75 122 117 109 62 76 78 
86 115 148 176 160 173 142 
77 96 101 80 88 62 60 
88 146 193 192 211 165 118 
74 118 115 109 98 51 71 
73 115 137 86 83 
76 131 187 226 204 
72 103 100 87 53 
77 99 140 126 108 
56 121 161 105 66 
71 93 160 201 192 
70 105 92 82 87 
71 124 168 198 159 
89 104 141 129 110 
64 113 138 120 51 
86 152 193 205 172 
68 105 285 60 59 
63 151 273 180 95 
77 133 167 113 60 
75 175 233 206 111 
66 132 153 122 66 
72 128 179 164 132 
86 115 141 111 83 
81 116 144 174 135 
62 104 168 104 79 
61 113 151 183 174 














































* Dog P, 7.4 Kg.; glucose 1.75 Gm./Kg. body weight (orally). 




mg./Kg. F % 1 1% 2 2% 3 
body wt. 
G.B.B. 2 - 107 167 145 101 85 63 
0 68 112 162 85 67 63 69 
0 86 115 141 111 83 50 66 
K.W. 2 80 125 177 183 173 152 120 
0 73 115 146 111 73 63 64 
W.O.G. 2 75 126 167 176 142 91 55 
0 75 142 175 136 86 59 68 
0 73 108 107 102 81 73 66 
1.47 a4 137 184 159 154 122 88 
0 82 123 162 158 102 86 98 
R.L.A. 2 79 105 165 176 149 85 74 
0 72 106 149 145 75 58 60 
H.M.Z. 2 77 144 172 163 109 70 66 
0 77 105 108 102 85 85 72 
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upon glucose tolerance of the polypeptide (fraction 1) extracted from the 
urine of each of the 33 diabetic proteinuric patients in which it was found. 
Reduced glucose tolerance and insulin resistance induced by the polypep- 
tide from patients W.W. and D.A.B. were demonstrated in another animal 
as well (Dog 0). The procedure for these tests was the same as previously 
described.7 Figures 2 and 3 show the results. Of interest is the fact that the 
peptide found in patient D.A.B. was no longer present after he had undergone 
surgical hypophysectomy. 
Elemental analysis of the diabetogenic polypeptide from patient W.W. 
shows the following: C 48.14 per cent, H 6.89 per cent, N 14.68 per cent, and 
S 1.49 per cent. These values are almost the same as those obtained upon the 
peptide isolated from the urine of patients with lipoatrophic diabetes.6 
Figure 4 shows the polyacrylamide gel electrophoretic patterns of fraction 
1 from a lipoatrophic diabetic (pattern 3) and from 3 diabetics with protein- 
uria (patterns 4, 5 and 6). For comparison (Fig. 5) disc electrophoresis was 
also performed on fraction 1 isolated from bovine (pattern 7) and human 
(pattern 8) pituitary glands. Further purification of these fractions by Se- 
phadex column chromatography is now in progress. 
DISCUSSION 
Since our report1 on the isolation of a diabetogenic polypeptide from the 
urine of patients with lipoatrophic diabetes and the chance observation that 
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it was present in a proteinuric maturity-onset diabetic, we have been seeking 
to find the material in other diabetic patients. The significance of the associated 
proteinuria was not appreciated initially. It is now apparent that the peptide 
was present in the urine of 33 of the 35 diabetics with proteinuria but was 
present neither in 32 nonproteinuric diabetics nor in 34 healthy subjects. 
In 1 of 7 nondiabetics with proteinuria, a small amount of material which 
precipitated at pH 4.1 was found but it was insufficient to test for biological 
activity. When the material is present in proteinuric urine, it is not related 
quantitatively to the amount of protein excreted. Nineteen (58%) of the 
33 patients excreting this peptide had detectable diabetic retinopathy of 
various grades and it is evident that all had some form of nephropathy. The 
observation that the diabetogenic peptide disappeared from the urine following 
hypophysectomy in the one such case in which it was studied, together with 
our ability to isolate a similar material from the adenohypophysis of beef, 
sheep, and swine, suggests that it originates in the pituitary gland. It is tempt- 
ing to suggest that this material might somehow be involved in the micro- 
angiopathy of diabetes mellitus. In recent studies with frozen human pituitary 
glands, we have succeeded in isolating a polypeptide (isoelectric point ap- 
proximately pH 4.1) which closely resembles the substance isolated from 
the urine of patients with proteinuria and diabetes mellitus. These studies 
will be detailed in another communication. 
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